Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Please provide your email address to receive an email when new articles are posted on . Multi-target stool DNA screening tests predicted neoplasia at follow-up colonoscopy more often than fecal ...

Roughly 10% of fecal immunochemical tests (FIT) used for colorectal cancer (CRC) screening by a safety-net health system contained unsatisfactory samples that could not be processed. And fewer than ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Increased use of FIT could improve CRC screening rates, especially among vulnerable populations Abstract: http://annals.org/aim/article/doi/10.7326/M18-2390 Editorial ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...